Dr. Antanas Grimalauskas is an associate in the Corporate Department of Latham & Watkins’ Hamburg office.

Antanas advises on transactional, general corporate law, and regulatory matters with a focus on the healthcare and life sciences industry.

Antanas studied law and completed his practical legal training in Berlin. During his practical legal training he worked as a trainee lawyer, inter alia, at the German Federal Ministry of Health and in Latham & Watkins’ corporate department in Hamburg.

Antanas' experience includes advising:

  • Cheplapharm on the acquisition of the worldwide commercial rights (excluding South Korea) for Gemzar® from Eli Lilly and Company
  • Demant on the acquisition of OHRWERK Group
  • International data science company in connection with the development of an AI-based virtual biopsy tool for prostate cancer 
  • Novo Nordisk on the acquisition of Cardior Pharmaceuticals

Bar Qualification

  • Rechtsanwalt (Germany)

Education

  • Second German State Exam, Higher Regional Court, Berlin, 2023
  • First German State Exam, Humboldt University, Berlin, 2021

Languages Spoken

  • German
  • English
  • Lithuanian
  • Russian